IRCCS AZIENDA OSPEDALIERO- UNIVERSITARIA DI BOLOGNA

Their core work

IRCCS AOU Bologna is a major Italian university hospital and clinical research institute (IRCCS designation) based in Bologna, specializing in advanced clinical care and translational research. Their H2020 involvement spans hematological diseases, gastrointestinal disorders, cardiovascular surgery, and pandemic response — reflecting their role as a multi-specialty hospital contributing patient cohorts, clinical expertise, and real-world data to European research consortia. They primarily serve as a third-party clinical site, providing access to patient populations and clinical infrastructure that large-scale EU studies require for validation and real-world evidence.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), the hospital focused on traditional clinical research: surgical trials for aortic aneurysm repair, cell therapy for graft-versus-host disease, and gastrointestinal disorder studies like IBS and cirrhosis. From 2020 onward, a clear digital shift emerged — projects increasingly involve federated learning, multi-omics, big data analytics, and connected health monitoring. This mirrors a broader hospital-wide move toward data-driven and AI-assisted clinical research, while maintaining their core strength in complex multi-organ disease management.

Moving firmly toward digital health and AI-assisted medicine, making them an increasingly relevant partner for projects that need clinical AI validation on real hospital data.

How they like to work

IRCCS AOU Bologna overwhelmingly participates as a third party (7 of 8 projects), meaning they are typically brought in by a direct partner to contribute clinical data, patient cohorts, or specialist medical expertise. They work within very large consortia — 156 unique partners across 28 countries — but their third-party status means they are a resource contributor rather than a project driver. For potential collaborators, this signals a reliable clinical site that can be mobilized for multi-center studies without taking on project management burden.

Connected to 156 unique partners across 28 countries, giving them one of the broadest clinical collaboration networks among Italian university hospitals in H2020. Their reach is pan-European with no single geographic cluster, reflecting their role as a go-to clinical site for large multi-center health studies.

What sets them apart

As an IRCCS-designated hospital (Italy's highest clinical research recognition), AOU Bologna offers something many academic partners cannot: direct access to large, diverse patient populations across multiple medical specialties under one institutional umbrella. Their unusual breadth — from hematology and liver disease to cardiovascular surgery and mental health — means a single partnership can cover multiple clinical domains. Their recent adoption of federated learning and AI tools positions them as a clinical validation site for health-tech companies and digital health consortia that need real hospital environments.

Highlights from their portfolio

• TREGeneration
  Their only project as a direct participant (EUR 627K funding), focused on the high-impact area of repairing tissue damage from graft-versus-host disease after stem cell transplant.
• GenoMed4ALL
  Combines their hematology expertise with federated learning and multi-omics — represents their clearest pivot toward AI-driven personalized medicine.
• ORCHESTRA
  Major pan-European COVID-19 response project connecting cohorts across countries, demonstrating their capacity to contribute to rapid-response public health research.